Search the TFS Resource Library

Search by keyword, or choose a Therapeutic Area to view all resources within that area of study.

  • All
  • Articles
  • Case Studies
  • Infographics
  • Reference Sheets
  • Webinars
  • White Papers
  • Other
  • Clear Filters
Found 72 Results
Page 1 of 12
Case Study

AI is changing how we answer the first question on every trial: can this be done, where and how fast?

TFS HealthScience is implementing AI to deliver feasibility assessments faster. See how AI and human judgement work together to answer every trial’s first question.

Download
Case Study

How our Medical Writing Team went from Synopsis to Protocol in two months

How the TFS Medical Writing team delivered a clinic-ready protocol in two months, from a single slide deck.

Download
White paper

FSP vs Full-service CRO: a plain-English guide for German and Swiss Biotech

A plain-English breakdown of FSP vs full-service CRO for DACH biotech, covering local regulatory context and what to look for in a partner.

Download
White paper

Navigating the Regulatory and Scientific Complexities of Combination Therapy Protocols

Combination therapy trials require clear, compliant protocols to manage complexity and risk. Download our white paper for expert medical writing insights on effective protocol development.

Download
Webinars

Managing Placebo Risk in Dermatology Trials

Gain practical strategies for managing placebo risk and ensuring credible, compliant dermatology trial results.

Watch Now
White paper

Rethinking Clinical Operations: A Smarter, Faster Playbook for Trial Success

Learn how results-driven frameworks, integrated digital systems, and innovative strategies are transforming clinical operations.

Download

Latest Articles

Found 195 Results
Page 1 of 22
Article

10 oncology trial readouts to watch for at ASCO 2026

Biomarker-defined populations. Rare cancers. Multi-country designs. As ASCO 2026 approaches, TFS HealthScience outlines the ten oncology trials that matter most and what they mean for sponsors planning their next programme.

Read Now
Article

From single-injection vision restoration to gene therapy: what precision ophthalmology means for trial design in 2026

Learn how ARVO 2026 signals a new era of precision ophthalmology, where smarter recruitment, imaging consistency and patient‑centric design demand deep‑tier partnerships like those offered by TFS.

Read Now
Article
News

Is your ClinicalTrials.gov results submission overdue?

The FDA reminded over 2,200 sponsors to submit overdue ClinicalTrials.gov results. This how TFS Medical Writing team can help.

Read Now
Article

The Value of Cross-Functional Expertise in Complex Oncology Clinical Trials

Experienced Oncology CROs with cross-functional expertise strengthen complex oncology clinical trials and accelerates clinical development.

Read Now
Article

Top 5 Challenges in Psoriasis Clinical Trials (and How to Overcome Them)

Psoriasis clinical trials face predictable hurdles, from patient recruitment shortfalls to regulatory complexity. This blog explores the five most common challenges and practical strategies sponsors can use to overcome them.

Read Now
Article

From Strategy to Patients: Adaptability and Innovation in Trial Design

Explore how adaptability, innovation, and patient focus can help sponsors rethink trial execution, from smarter sourcing models to the role of AI in oncology.

Read Now
Article

Navigating Today’s Clinical Trials: Strategies for Sponsors Facing a Shifting Landscape

Explore how sponsors can stay ahead of evolving regulatory demands, tech shifts, and enrollment pressures in today’s complex clinical trial landscape.

Read Now
Article

Rare Neurological Disease Trials: Smarter Design with Natural History, External Controls, and Real-World Evidence

Discover how natural history data, external controls, and RWE are reshaping rare neurological disease trials for smarter, regulatory-ready design.

Read Now
Article

ICH E6(R3) Is Here. Is Your Trial Ready?

Discover how TFS is helping sponsors prepare for ICH E6(R3) with proactive oversight, modern technologies, and quality-first trial design.

Read Now